Advanced Biomed Inc. income statement ADVB

In fiscal 2026, which ended Jun 30, 2026, Advanced Biomed Inc. reported revenue of $127,637. Net income was $6.7 million, a profit margin of 5231.3%. The operating loss came to $6.2 million, an operating margin of -4883.8%. Diluted earnings per share were $5.33.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Jun 30, 2025
Revenue
0
—
Research and development
—
1
Selling, general and administrative
5
+325.9%
1
Operating income
-6
—
Other non-operating income (expense)
-0
+91.7%
-0
Pretax income
-6
-476.4%
-1
Income tax
-0
—
Net income
7
+304.9%
-3
Basic EPS
5.33
+267.6%
-3.18
Diluted EPS
5.33
+267.6%
-3.18
Weighted average shares, basic
1
+22.1%
1
Weighted average shares, diluted
1
+22.1%
1
Other measures
Depreciation and amortization
—
0
Margins
Operating margin
-4,883.80%
—
Pretax margin
-4,906.48%
—
Profit margin
5,231.30%
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

Company profile

Industry
Services-Medical Laboratories (SIC 8071)
Listed as
ADVB (Nasdaq)
Fiscal year ends
June 30
Incorporated in
NV
Headquarters
Reno, NV
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1941029

Other Services-Medical Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.